The FDA’s new draft Guidance on Interchangeability of biosimilars will require most biosimilars' sponsors to conduct studies showing that switching between a biosimilar and its Reference product poses no greater risk than continuing to use the reference product. The guidance recommended designs for switching studies, as well as integrated trials to show that a compound is both biosimilar to and interchangeable with its reference biologic.